Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth

Nubeqa, Kerendia Driving Revenue; New Launches On The Way

Scrip spoke with Bayer commercial and business development heads Christine Roth and Jurgen Eckhardt about sales growth, product launches and dealmaking priorities in 2025 and beyond.

New launches and added indications will fuel growth in 2025 as Xarelto revenue declines (Shutterstock)

More from Strategy

More from Scrip